Agilent secures CE-IVD Mark for cervical cancer test

LabPulse.com staff writers
May 10, 2022
2019 11 07 23 47 6944 Squamous Epithelial Cells Cervical 400

Agilent Technologies has secured the CE-IVD Mark in Europe for its companion diagnostic test for identifying cervical cancer patients eligible for treatment with Merck's Keytruda (pembrolizumab) immunotherapy.

PD-L1 is an antibody expressed by cervical cancer tumors and is a key biomarker for predicting response to anti-PD-L1 therapies like Keytruda, according to Agilent. The company's PD-L1 IHC 22C3 pharmDx companion diagnostic identifies cervical cancer patients with a PD-L1 combined positive score of one or more, which indicates that they could benefit from treatment with Keytruda, the company said.

Latest in Cervical Cancer
Genius Review Station Social
Hologic receives FDA clearance for digital cytology scanner platform in U.S.
February 2, 2024
Hpv Infection Social
Mailed HPV home test kits doubled cervical cancer screening rates in study
May 12, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Squamous Epithelial Cells Cervical Social
AACC provides recommendations for detecting cervical cancer
March 6, 2023
Related Stories
Lung Cancer Hotspot Social
Non Small Cell Lung Cancer
Agilent announces FDA approval for non-small cell lung cancer CDx
Financials Growth Revenue Business Social
Financial Results
Agilent Technologies Q4 revenues rise 11%
2022 09 01 16 02 3207 Gas Chromatography Lab2 400
Chromatography
Agilent, Mettler Toledo collaborate on chromatography
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Cervical Cancer
Hologic receives FDA clearance for digital cytology scanner platform in U.S.
By Liz Carey
Acknowledging human papillomavirus (HPV) as a causative agent for cervical cancer, the new system is designed to complement molecular testing for HPV with cotesting for cervical cancer.
February 2, 2024
Genius Review Station Social
Mailed HPV home test kits doubled cervical cancer screening rates in study
By Elissa Wolfson
Mailing human papillomavirus (HPV) self-collection kits for at-home use improved cervical cancer screening in under-screened, low-income women by nearly two-fold.
May 12, 2023
Hpv Infection Social
Mailing HPV self-sampling kits for cervical cancer screening was cost-effective in study
By Elissa Wolfson
The study, published Wednesday in JAMA Network Open, supports mailing HPV kits as an efficient outreach strategy for increasing screening rates among eligible women.
March 22, 2023
Genetics Dna Money Social
AACC provides recommendations for detecting cervical cancer
By LabPulse.com staff writers
The guidance aims to update healthcare and laboratory medicine professionals about the latest advancements in this field, and to help them select the most effective cervical cancer detection strategy for their patients, AACC said.
March 6, 2023
Squamous Epithelial Cells Cervical Social
BioReference offering Roche Diagnostics cytology test for women at high risk for HPV
By LabPulse.com staff writers
The test uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results.
February 9, 2023
Hpv Infection Social
Fujirebio Europe secures distribution rights for Self-Screen's methylation-specific molecular assay
By LabPulse.com staff writers
The test identifies women at high risk by detecting elevated methylation levels of cancer biomarkers, Fujirebio said, adding that it has been validated for both physician sample collection and sample self-collection.
October 11, 2022
Squamous Epithelial Cells Cervical
Week in Review: Roche’s new MDx system, HIV world market, cervical cancer testing disparities, and more
By Leo O'Connor
Dear LabPulse.com member,
August 24, 2022
Combining imaging with liquid biopsy for cervical cancer
By LabPulse.com staff writers
The authors -- researchers at the University of California San Diego (UCSD) and Johns Hopkins University -- noted that liquid biopsy has emerged as a promising tool that may be able to overcome some of imaging's drawbacks.
August 22, 2022
2022 08 23 20 53 9627 Cancer Radiotherapy 400
Disparities seen in cervical cancer incidence, screening
By LabPulse.com staff writers
But white women have seen a greater annual increase in cervical cancer rates, particularly in adenocarcinomas, noted a team led by Dr. Alex Francoeur from the University of California, Los Angeles. The researchers found that white women have lower rates of guideline screening and vaccination compared with Black women.
August 18, 2022
2019 11 07 23 47 6944 Squamous Epithelial Cells Cervical 400
Roche launches HPV self-sampling solution
By LabPulse.com staff writers
The patient self-collects a sample while at a healthcare facility, following instructions provided by a healthcare worker. Then the clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on one of its molecular instruments.
June 15, 2022
2020 07 29 23 56 6775 Hpv Infection 400
Seegene develops '3 Ct' assay for HPV infection
By LabPulse.com staff writers
The Allplex HPV HR assay detects 14 high-risk HPV types that cause cervical cancer. The assay provides the individual Ct value of each cancer type, allowing quantitative analysis to determine the infection level. The test is expected to be launched in the first half of 2022.
April 26, 2022
2019 05 17 20 09 8391 Hpv 400
Dalrada Health completes cervical cancer screening kit trial
By LabPulse.com staff writers
Results from the trial were published this month in the Indian Society of Perinatology and Reproductive Biology (IJOPARB) journal. Study participants were screened for cervical cancer with cerVIA, which showed an accuracy of 91%, according to the firm. The test is patent-pending, Dalrada said.
April 24, 2022
2019 11 07 23 47 6944 Squamous Epithelial Cells Cervical 400
Page 1 of 3
Next Page